TrustBIX - President and CEO, Hubert Lau.
President and CEO, Hubert Lau.
Source: nait.ca.
  • TrustBIX (TBIX) has announced a letter of intent and concurrent private placement
  • The company signed the non-binding letter of intent to acquire a Canadian private company that provides tracking solutions for high-value agricultural equipment
  • It will issue up to 30M shares as consideration
  • It intends to raise up to C$2M to finance the acquisition
  • TrustBIX provides agri-food traceability and chain of custody value solutions
  • TrustBIX (TBIX) closed up by 6.06 per cent trading at $0.175 per share

TrustBIX (TBIX) has announced a letter of intent and concurrent private placement.

The company signed the non-binding letter of intent to acquire a Canadian private company that provides tracking solutions for high-value agricultural equipment.

It will issue 10M shares plus up to an additional 20M shares based on certain financial milestones within one year after closing.

The parties intend to negotiate a definitive agreement by February 18, 2022.

“We view this transaction as another key step in our growth strategy for building depth and scale in the agri-tech industry,” stated Hubert Lau, CEO of TrustBIX.

As part and parcel of the acquisition, TrustBIX intends to complete a non-brokered private placement of up to 11,111,111 units priced at C$0.18 for proceeds of up to $2M.

Each unit is comprised of one TrustBIX common share and one common share purchase warrant.

Each warrant entitles the holder to purchase one common share priced at $0.30 for 18 months from the date of closing.

TrustBIX provides agri-food traceability and chain of custody value solutions.

TrustBIX (TBIX) closed up by 6.06 per cent trading at $0.175 per share.

More From The Market Online

Westinghouse Electric files for US IPO

Westinghouse Electric Company, jointly owned by Cameco and Brookfield Renewable Partners, confidentially filed for a US IPO.

Buzz on the Bullboards: Contracts, cashflows, and delistings

Uncertainty around Iran has weighed on sentiment, reminding investors that even strong stories can be overshadowed by geopolitical risk.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.